SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-276394
Filing Date
2022-11-03
Accepted
2022-11-03 07:35:32
Documents
13
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d352800d8k.htm   iXBRL 8-K 26587
2 EX-99.1 d352800dex991.htm EX-99.1 93920
  Complete submission text file 0001193125-22-276394.txt   254315

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20221103.xsd EX-101.SCH 2903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20221103_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20221103_pre.xml EX-101.PRE 10844
7 EXTRACTED XBRL INSTANCE DOCUMENT d352800d8k_htm.xml XML 3208
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 221356258
SIC: 2834 Pharmaceutical Preparations